Skip to main content
Premium Trial:

Request an Annual Quote

Nasdaq Approves Orchid s Bid to Secure $16M in Financing Without Shareholders Approval

NEW YORK, March 21 - Orchid BioSciences said yesterday that it had received a waiver from Nasdaq, allowing it to go ahead with a private financing of $16 million without seeking shareholders' approval.

 

Nasdaq granted the exception on the grounds that securing shareholder approval might seriously jeopardize the financial viability of the company.

 

Orchid intends to sell up to 1,600 shares of newly issued convertible preferred stock, each convertible into approximately 22,222 shares of common stock. Each preferred share in the proposed offering will have a purchase price of $10,000 and will include a warrant to purchase approximately 6,667 shares of Orchid's common stock. The shares in the proposed offering would be convertible into common stock at a conversion price of $0.45, and the warrants would be exercisable at $0.45 per share, according to the company.

 

The buyers of the new offering will be select institutional investors, Orchid said.

 

For further information, see the company statement.

 

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.